Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (3506)	4/21/2001 12:35:11 PM
From: JOEBT1	Read Replies (1) \| Respond to of 52153

Rick-< the route to superior returns in biotech> Another route to superior returns in biotech: 1-Invest in "depressed" biotechs with an advanced clinical pipeline with high probability products on the market in 6 months to 3 years, eg, PRCS, SCIO, SEPR,HGSI,NBIX,IMGN, etc. 2-No limit on market cap provided that cash, technology value, discounted earnings project a much higher market cap, 2 to 3 times, over the next 2 to 4 years. Ten baggers will not be as common as 1 to 4 years ago when many biotechs were significantly overvalued in the the mania market of the .Coms. However ,if anybody can do it, you can. Your humble servant, :-) Joe

To: scaram(o)uche who wrote (3506)	4/21/2001 4:24:46 PM
From: aknahow	Read Replies (2) \| Respond to of 52153

Since I hear she does not like XOMA, I was pleased she did not name names. <g> She must have some smarts since she is in agreement with you on at least something. She is a big bull on BGEN, dislikes DNA and talks down Xanelim at many analyst meetings.